Last reviewed · How we verify
P2Y12 antagonist monotherapy
P2Y12 antagonists block the P2Y12 adenosine diphosphate receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.
P2Y12 antagonists block the P2Y12 adenosine diphosphate receptor on platelets to inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome, Percutaneous coronary intervention, Stroke prevention in patients with acute ischemic stroke or transient ischemic attack.
At a glance
| Generic name | P2Y12 antagonist monotherapy |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | P2Y12 receptor antagonist |
| Target | P2Y12 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
P2Y12 is a G-protein coupled receptor on platelets that mediates ADP-induced platelet activation and aggregation. By antagonizing this receptor, P2Y12 inhibitors reduce platelet clumping and blood clot formation. This antiplatelet effect is used to prevent thrombotic cardiovascular events in patients at risk.
Approved indications
- Acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI)
- Secondary prevention of atherothrombotic events in patients with prior myocardial infarction or stroke
- Peripheral arterial disease
Common side effects
- Bleeding (major and minor)
- Dyspnea
- Bradycardia
- Gastrointestinal bleeding
Key clinical trials
- Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR (PHASE4)
- Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent (NA)
- Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction
- Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES (NA)
- Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P2Y12 antagonist monotherapy CI brief — competitive landscape report
- P2Y12 antagonist monotherapy updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI